Serum secretogranin III concentrations were increased in subjects with metabolic syndrome and independently associated with fasting plasma glucose levels

研究成果: Article同行評審

1 引文 斯高帕斯(Scopus)

摘要

Secretogranin III (SCG3) plays a crucial role in the biogenesis of secretory granules in endocrine cells, and thus affects glucose homeostasis by regulating insulin secretion by pancreatic beta cells. Insulin resistance and compensatory hyperinsulinemia are hallmarks of metabolic syndrome (MetS). However, the role of SCG3 in MetS remains unclear. Therefore, we investigated the relationship between serum SCG3 levels and metabolic parameters in subjects with and without MetS. This was a case control study, and 295 subjects were recruited. Serum SCG3 concentrations were compared between groups. Associations between SCG3 levels and clinico-metabolic parameters were also examined. We found serum SCG3 levels were higher in the MetS group than non-MetS group (122.6 ± 79.2 vs. 90.6 ± 58.5 nmol/L, p = 0.009). Specifically, elevated SCG3 levels were found in subjects with high fasting plasma glucose (FPG) levels, central obesity, or hypertriglyceridemia. Additionally, MetS was an independent factor of serum SCG3 levels in multivariate linear regression analyses. Moreover, FPG, free fatty acids, and waist circumference were positively associated with serum SCG3 concentrations after adjusting for insulin levels, high-sensitivity C-reactive protein, and cardiovascular risk factors. In conclusion, serum SCG3 concentrations were higher in subjects with MetS and were independently associated with FPG levels.

原文English
文章編號1436
期刊Journal of Clinical Medicine
8
發行號9
DOIs
出版狀態Published - 2019 9月

All Science Journal Classification (ASJC) codes

  • 醫藥 (全部)

指紋

深入研究「Serum secretogranin III concentrations were increased in subjects with metabolic syndrome and independently associated with fasting plasma glucose levels」主題。共同形成了獨特的指紋。

引用此